ProCE Banner Activity

ADJUVANT-CTONG 1104: Final OS Analysis of Phase III Study of Adjuvant Gefitinib vs Chemotherapy in Chinese Patients With Resected EGFR-Mutated NSCLC

Slideset Download
Conference Coverage
At a median follow-up of 80 months, adjuvant gefitinib significantly improved DFS but not OS vs vinorelbine/cisplatin in Chinese patients with completely resected stage IIA-IIIA (N1-N2) EGFR-mutated NSCLC.

Released: June 09, 2020

Expiration: June 08, 2021

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie Inc.

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Jazz Pharmaceuticals

Jazz Pharmaceuticals Inc

Karyopharm Therapeutics

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer and EMD Serono